Brooklyn Investment Group’s Astria Therapeutics ATXS Stock Holding History

Brooklyn Investment Group’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-26,558	Closed	-$345K	–	1848
2025 Q4	$345K	Buy	26,558 +15,114	+132%	+$181K	0.02%	936
2025 Q3	$63.7K	Hold	11,444	–	–	0.01%	657
2025 Q2	$61.3K	Buy	11,444 +2,750	+32%	+$13.3K	0.01%	1222
2025 Q1	$46.4K	Buy	8,694 +7,957	+1,080%	+$55.7K	0.01%	811
2024 Q4	$6.59K	Buy	+737	New	+$7.83K	﹤0.01%	1126

Brooklyn Investment Group's ATXS Position: Q1 2026 in Review

Brooklyn Investment Group sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 26,558 shares — an estimated $345K sold.

Brooklyn Investment Group first reported a position in ATXS in Q4 2024 and held it in 5 quarters. The position peaked at $345K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Brooklyn Investment Group reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Brooklyn Investment Group sold 26,558 Astria Therapeutics shares in Q1 2026, an estimated $345K.
Brooklyn Investment Group first reported a position in Astria Therapeutics in Q4 2024 and held it in 5 quarters.
Brooklyn Investment Group's Astria Therapeutics position peaked at $345K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.